focal epilepsy


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia, Wikipedia.

fo·cal ep·i·lep·sy

epilepsy of various etiologies characterized by focal seizures or secondarily generalized tonic-clonic seizures. Ictal symptoms are often related to the brain region where the seizure begins focally.

focal epilepsy

n.
An epileptic condition in which disturbance in a localized area of cerebral function causes focal seizures.

focal epilepsy

Neurology A seizure disorder arising from a specific population of neurons, often in a background of a tumor or scar from recent injury; FE may be triggered through a kindling reaction. See Seizures.

fo·cal ep·i·lep·sy

(fō'kăl ep'i-lep'sē)
Epilepsy of various etiologies characterized by localized seizures or secondarily generalized tonic-clonic seizures. Ictal symptoms are often related to the brain region where the seizure begins focally.
Synonym(s): localization-related epilepsy (2) .
References in periodicals archive ?
This study was designed to evaluate the efficacy and safety of brivaracetam(100 and 200 mg/day, without titration) compared to placebo, as adjunctive treatment in adult focal epilepsy patients with partial-onset seizures, not fully controlled despite treatment with one or two concomitant antiepileptic drugs (AEDs).
Additional products under development include: NeuroCell(TM)-PD for Parkinson's disease; porcine neural cells for stroke, focal epilepsy and intractable pain; porcine spinal cord cells for spinal cord injury; NeuroCell(TM)-HD for Huntington's disease; porcine liver cells for acute liver failure; human liver cells for cirrhosis; and porcine retinal pigment epithelial cells for macular degeneration.
The results from this trial provide further evidence for the added value of adjunctive VNS Therapy in patients with drug-resistant focal epilepsy who are not candidates for surgical resection.
Temporal lobe epilepsy accounts for nearly 20 percent of all epilepsy and an estimated 70 percent of drug resistant focal epilepsy cases.
Surgery is an increasingly common alternative for those suffering from drug-resistant focal epilepsy.
Products under development for the treatment of neurological disorders include: NeuroCell(TM)-PD for Parkinson's disease and NeuroCell(TM)-HD for Huntington's disease, both of which are being developed in a joint venture with Genzyme Corporation, NeuroCell(TM)-FE for focal epilepsy, porcine neural cells for stroke and intractable pain and spinal cord cells for spinal cord injury.
Today, PET is most widely used for diagnostic purposes with patients experiencing focal epilepsy, brain trauma, brain tumors, stroke, dementias, cancer and heart disease.
We are also funding a Phase 1 clinical trial of NeuroCell(TM)-FE for focal epilepsy and have recently been cleared by the FDA to begin Phase 1 clinical trials of human hepatocytes for cirrhosis, porcine hepatocytes for acute liver failure, and porcine neurons for stroke.
Products under development for the treatment of neurological disorders include: NeuroCell(TM)-PD for Parkinson's disease and NeuroCell(TM)-HD for Huntington's disease, both of which are being developed in a joint venture with Genzyme Corporation's Tissue Repair Division, NeuroCell(TM)-FE for focal epilepsy, porcine neural cells for stroke and intractable pain and spinal cord cells for spinal cord injury.